A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients

Abstract Background There is an unmet need to identify novel predictive biomarkers that enable more accurate identification of individuals who can benefit from immune checkpoint inhibitor (ICI) therapy. The US FDA recently approved tumor mutational burden (TMB) score of ≥ 10 mut/Mb as a threshold fo...

Full description

Bibliographic Details
Main Authors: Xilin Hu, Jing Guo, Jianguang Shi, Da Li, Xinjian Li, Weijun Zhao
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Pulmonary Medicine
Subjects:
NSCLC
ICI
Predictive biomarker
Tumor mutational burden
Gene mutation signature
Nomogram
Online Access:https://doi.org/10.1186/s12890-023-02512-6

Internet

https://doi.org/10.1186/s12890-023-02512-6

Similar Items